发明名称 Inhibitors of Beta-Hydroxylase for Treatment of Cancer
摘要 The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydroxylase (e.g., Asparatyl (asparaginyl) β-hydroxylase (ASPH)), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.
申请公布号 US2015210677(A1) 申请公布日期 2015.07.30
申请号 US201314430101 申请日期 2013.09.20
申请人 Midwestern University 发明人 Wands Jack R.;de la Monte Suzanne;Aihara Arihiro;Olsen Mark Jon;Thomas John-Michael
分类号 C07D417/04;C12Q1/26;C07D405/04;C07D405/12;C07D307/32;C07D409/04 主分类号 C07D417/04
代理机构 代理人
主权项 1. An asparatyl (asparaginyl) beta-hydroxylase (ASPH) inhibitory compound for use in a method of reducing proliferation, migration, invasion, or metastasis of a tumor cell in the treatment of cell proliferative disorder, comprising contacting said tumor cell with the ASPH inhibitory compound, wherein the ASPH inhibitory compound is of Formula Ia or Ib: or a salt, ester, metabolite, prodrug, or solvate thereof, wherein Ar1 is substituted or unsubstituted C6-C20 aryl or 5 to 20-membered heteroaryl; X is C(O), C(S), or S(O)2; W1 is a single bond, O, CR50R51, or NR52 when X is CO and W1 is a single bond, CR50R51, or NR52 when X is SO2; and each of R50, R51, R52, and R53 independently is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C6-C20 aryl, substituted or unsubstituted C7-C26 arylalkyl, substituted or unsubstituted 5 to 20-membered heteroaryl, and substituted or unsubstituted 6-26 membered heteroarylalkyl.
地址 Downers Grove IL US